Cardio-renal and metabolic benefits of empagliflozin: additional indication and change in indication restrictions

Czech version

Authors: Ingrid Dravecká
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice
Published in: Diab Obez 2023; 23(46): 113-117
Category:

Overview

People with type 2 diabetes mellitus (T2D) have a 2–4-fold increased risk of cardiovascular disease (CVD), which is potentiated by the presence of microvascular and macrovascular chronic complications of the disease. The cardiovascular and renal systems are interconnected through hormonal and humoral mechanisms. Their diseases progress gradually, with the presence of one worsening the course of the other. This cardiorenal continuum is initiated by risk factors that subsequently lead to heart failure and terminal renal failure. In addition to optimal metabolic compensation of T2D, treatment of dyslipidemia, hypertension and weight loss, it is necessary to choose for the patient a medical therapy that could influence either the risk or the course of CVD and renal disease. Beneficial effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been observed in all stages of the cardiorenal continuum, from patients with DM and multiple risk factors to those with CVD, heart failure or chronic kidney disease) independent of DM. Empagliflozin in the EMPA-REG OUTCOME trial in subjects with T2D and KVO reduced cardiovascular (38%) and overall (32%) mortality, reduced the risk of hospitalizations for heart failure (35%), and led to slower progression (39%). The nephroprotective effect of empagliflozin was also confirmed in the EMPA-KIDNEY study, which included subjects with/without DM, with/without CVD with different glomerular filtration rate and albuminuria. Treatment with empagliflozin resulted in a 28% reduction in progression of chronic kidney disease or CV death. In the EMPEROR-Reduced and EMPEROR-Preserved trials, empagliflozin led to a significant reduction in the risk of death, hospitalizations for heart failure, or the need for urgent evaluation for heart failure with the need for intensification of therapy, independent of ejection fraction and the presence of DM.

Keywords:

cardiorenal continuum – cardiovascular disease (CVD) – chronic kidney disease (CKD) – empagliflozin – EMPA-KIDNEY study – EMPA-REG OUTCOME study – EMPEROR-Preserved study – EMPEROR-Reduced study – type 2 diabetes mellitus (T2D)

Sources

Literatúra
Zinman B, Inzucchi SE, Lachin JM et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13: 102. Dostupné z DOI: <http://dx.doi.org/10.1186/1475–2840–13–102>.
Fontes-Carvalho R, Santos-Ferreira D, Raz I et al. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol 2022; 29(9): 1352–1360. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwab034>.
Packer M, Butler J, Zannad F et al. Effect of Empaglflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation 2021; 144(16): 1284–1294. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056824>.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
Packer M, Anker SD, Butler J et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation 2021; 143(4): 326–336. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051783>.
Anker J, Butler J, Filippatos G et al. Empagliflozin in heart Failure ith a Preserved Ejection Fraction. N Engl Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.
Voors AA, Angermann CE, Teerlink JR et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022; 28(3): 568–574. Dostupné z DOI: <http://dx.doi.org/10.1038/s41591–021–01659–1>.
Mokdad AH, Reiner RC, Murray D et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395(10225): 709–733. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(20)30045–3>.
Herrington WG, Staplin N, Wanner C et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.
Shin Y, Moon JH, Chin HJ et al. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinol Metab 2020; 35(2): 329–338. Dostupné z DOI: <http://dx.doi.org/10.3803/EnM.2020.35.2.329>.
Inzucchi SE, Zinman B, Fitchett D et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018; 41(2): 356–363. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1096>.
Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res 2021; 117(1):74–84. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvaa064>.
Kam-Tao Li P, Garcia-Garcia G, Li SF et al. Kidney health fo everyone everywhere – from prevention to detection and equitable access to care. Clin Nephrol 2020; 93(3): 111–122. Dostupné z DOI: <doi: 10.5414/CNWKDEditorial>.